Tarsus Pharmaceuticals (TARS) Invested Capital (2019 - 2026)

Tarsus Pharmaceuticals' Invested Capital history runs 8 years deep, the most recent figure standing at $421.5 million for Q1 2026.

• In Q1 2026, Invested Capital rose 1.71% year-over-year to $421.5 million; the TTM figure through Mar 2026 stood at $421.5 million (up 1.71% YoY), while the FY2025 annual figure was $415.9 million, up 40.31% from the prior year.
• Invested Capital was $421.5 million for Q1 2026 at Tarsus Pharmaceuticals, up from $415.9 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $421.5 million in Q1 2026 to a low of $168.4 million in Q1 2022.
• Historically, Invested Capital has averaged $293.1 million across 5 years, with a median of $296.4 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Invested Capital declined 28.42% in 2023, then jumped 87.9% in 2024.
• A 5-year view of Invested Capital shows it stood at $212.3 million in 2022, then rose by 6.82% to $226.8 million in 2023, then jumped by 30.67% to $296.4 million in 2024, then jumped by 40.31% to $415.9 million in 2025, then advanced by 1.37% to $421.5 million in 2026.
• The last three Invested Capital figures came in at $421.5 million (Q1 2026), $415.9 million (Q4 2025), and $407.4 million (Q3 2025), per Business Quant data.